Thus, the purpose of this study was to analyze the safety and tolerability of BRAFi and BRAFi-based combination therapy (MEKi or anti-PD-1 antibody) in Chinese patients with BRAF V600E/K mutation-positive metastatic melanoma. The gene discussed is BRAF; the disease is metastatic melanoma.